Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab-Reference-Cited by-同舟云学术

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab

Published:2009-09 Issue:9 Volume:15 Page:1302-1307
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Afif Waqqas,Leighton Jonathan A.,Hanauer Stephen B.,Loftus Edward V.,Faubion William A.,Pardi Darrell S.,Tremaine William J.,Kane Sunanda V.,Bruining David H.,Cohen Russell D.,Rubin David T.,Hanson Karen A.,Sandborn William J.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference13 articles.

1. Tumour necrosis factor and Crohn's disease.

2. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

3. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial

4. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

5. An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with ulcerative colitis who have normalized histology are clinically stable after de-escalation of therapy;npj Gut and Liver;2024-08-02

2. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients;Inflammopharmacology;2024-07-10

3. Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis;Pharmacological Research;2024-04

4. Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease;Journal of Clinical Medicine;2023-10-27

5. Therapeutic Antibodies in Medicine;Molecules;2023-09-05